Literature DB >> 8362228

Erythromycin treatment is beneficial for longstanding Moraxella catarrhalis associated cough in children.

J Darelid1, S Löfgren, B E Malmvall.   

Abstract

The benefits of antibiotic treatment and a nasopharyngeal culture in children with longstanding cough were analysed in a prospective randomized open study. Clinically suspected pertussis was excluded. Of 40 children given erythromycin for 7 days, 35 (88%) recovered in one week, compared with 17/47 (36%) untreated (p < 0.0001). Erythromycin eliminated Moraxella catarrhalis from the nasopharynx in 21/31 children (68%), compared with spontaneous disappearance in 7/35 (20%) untreated controls (p < 0.001). Purulent bronchitis or otitis media occurred in 2 children (5%) in the treatment group and in 21 (45%) in the control group (p < 0.01). To evaluate the clinical role of isolated pathogens, the 47 untreated subjects were studied. Seven of 35 children harbouring M. catarrhalis recovered, compared with 8/12 in whom this bacterium was absent (p < 0.01). No correlation was found between the isolation of Haemophilus influenzae or Streptococcus pneumoniae and the clinical outcome. Children with persistent cough > 10 days may benefit from erythromycin treatment. M. catarrhalis in the nasopharynx indicates prolonged symptoms and increased risk of bacterial complications.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8362228     DOI: 10.3109/00365549309008506

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  In children with prolonged cough, does treatment with antibiotics have a better effect on cough resolution than no treatment?: Part A: Evidence-based answer and summary.

Authors:  Emily J Bailey; Ab Chang
Journal:  Paediatr Child Health       Date:  2008-07       Impact factor: 2.253

2.  Systematic review of the treatment of upper respiratory tract infection.

Authors:  T Fahey; N Stocks; T Thomas
Journal:  Arch Dis Child       Date:  1998-09       Impact factor: 3.791

Review 3.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

4.  Colonization and infection with Moraxella catarrhalis in childhood.

Authors:  R Berner; R F Schumacher; M Brandis; J Forster
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

Review 5.  Antibiotics for the common cold and acute purulent rhinitis.

Authors:  Tim Kenealy; Bruce Arroll
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

Review 6.  ERS statement on protracted bacterial bronchitis in children.

Authors:  Ahmad Kantar; Anne B Chang; Mike D Shields; Julie M Marchant; Keith Grimwood; Jonathan Grigg; Kostas N Priftis; Renato Cutrera; Fabio Midulla; Paul L P Brand; Mark L Everard
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

Review 7.  Antibiotics for prolonged wet cough in children.

Authors:  Julie M Marchant; Helen L Petsky; Peter S Morris; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2018-07-31

8.  Cough: are children really different to adults?

Authors:  Anne B Chang
Journal:  Cough       Date:  2005-09-20

9.  Developing a core outcome set for children with protracted bacterial bronchitis.

Authors:  Francis J Gilchrist; Imran Ali; Malcolm Brodlie; Will D Carroll; Bridget Kemball; James Walker; Ian Sinha
Journal:  ERJ Open Res       Date:  2020-02-10

10.  Upper airway viruses and bacteria and clinical outcomes in children with cough.

Authors:  Kerry-Ann F O'Grady; Keith Grimwood; Theo P Sloots; David M Whiley; Jason P Acworth; Natalie Phillips; Julie Marchant; Vikas Goyal; Anne B Chang
Journal:  Pediatr Pulmonol       Date:  2016-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.